Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001513162-18-000250
Filing Date
2018-10-01
Accepted
2018-10-01 17:33:10
Documents
1
Period of Report
2018-09-27

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 3  
1 PRIMARY DOCUMENT primary_doc.xml 3 2035
  Complete submission text file 0001513162-18-000250.txt   3599
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Issuer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
SIC: 8071 Services-Medical Laboratories

Mailing Address C/O AEOLUS PHARMACEUTICALS, INC. 23811 INVERNESS PLACE LAGUNA NIGUEL CA 92677
Business Address
Cavalier David (Reporting) CIK: 0001289783 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37492 | Film No.: 181098635